France

France has a long psychopharmacology tradition, but the current wave is a restart after decades of legal and institutional closure, not the continuation of a once-normal treatment model. The legal closure is easier to source than early clinical enthusiasm: the modern French framework is anchored in the narcotics orders consolidated around the 1990 text, which place classical psychedelics under strict control and prohibit ordinary manufacture, trade and use outside authorised exceptions. #

In 2005, France further tightened the position around ayahuasca-related materials by adding Banisteriopsis caapi, Psychotria viridis, Peganum harmala and related alkaloids to the narcotics list. That makes France a poor fit for any claim of a recognised ceremonial or plant-medicine carve-out in the official framework reviewed here. #

The contemporary restart first became visible through adjacent medicines and suicidality research rather than through routine classical psychedelic care. Spravato entered the French hospital and collectivity framework in 2020, while French investigators contributed a major randomised controlled ketamine study for acute suicidal ideation, published in 2022. France's broader policy style on controlled therapeutics favours staged pilots and tightly managed frameworks rather than open commercial access. # # #

By 2024-2026 the restart had become more tangible. Nimes advanced France-based psilocybin dosing and publication; Paris opened a COMP006 site and developed PSILOTRAZ; and the Paris neuropsychiatry ecosystem built a more explicit scholarly and professional infrastructure around psychedelic medicine. The 2026 ketamine CPC is therefore part of a broader pattern: France is slowly expanding controlled psychiatric innovation without opening a broad commercial market. # # # # # # #

The national centre of gravity is Paris, with Nimes as the clearest classical-psychedelic trial node, and Marseille as a smaller but visible humanities and public-discourse node. Paris matters because it combines regulator proximity, major psychiatry institutions, professional organisation, protocol development and a phase 3 industry interface. Nimes matters because it has actually dosed patients and published psilocybin results. # # # # # #

In Paris, the pivotal actors are GHU Paris, the Paris Brain Institute and the wider neuropsychiatry network around Luc Mallet. Public-facing programme pages describe funded LSD work in alcohol use disorder and obsessive-compulsive disorder, while the CNRS / Paris Cite ARCHE programme has become an important interdisciplinary platform for research on the social, historical and clinical worlds of psychedelics. These are ecosystem and protocol-development signals, not evidence of broad patient access. # # # #

Nimes is where the French classical-psychedelic clinical pipeline is currently most concrete. CHU Nimes has registered and run psilocybin studies in treatment-resistant depression and psychogenic non-epileptic seizures, and its PAD study has already yielded a peer-reviewed 2025 publication plus a 2026 mechanistic and qualitative follow-up. The work also connects into addiction-psychiatry expertise around Montpellier and the suicidality research environment associated with Philippe Courtet and colleagues. # # # # #

Marseille is not the main clinical-access hub, but it does matter for ecosystem mapping through Aix-Marseille University and Imera discussions on the renaissance of psychedelics in psychiatry. Separately, the Universite de Picardie Jules Verne / GRAP / INSERM translational cluster in Amiens is important for alcohol-use-disorder work around psilocybin and LSD, but those projects should be labelled as preclinical or programme-development activity unless public clinical-trial entries appear. # # #

Over the next 12-24 months, the most likely French changes are evidentiary rather than legislative. Expect more readouts from existing psilocybin work in Nimes, clearer movement on PSILOTRAZ in Paris, and continued discussion of how classical-psychedelic protocols should be staffed, standardised and ethically governed in hospital psychiatry. This will probably strengthen the research base without creating broad routine access. # # # # # #

On regulation and payer policy, any classical-psychedelic move in France would still require several sequential steps: mature clinical evidence, European authorisation where relevant, French HTA and payer positioning, care-pathway design, and workforce preparation. Even where global sponsor momentum exists, French patient access would not follow automatically. This is already visible in esketamine, where authorisation and restricted institutional funding have not translated into a simple ambulatory reimbursement story. # # # #

The likeliest near-term access change is therefore on the ketamine side: operational uptake, pharmacovigilance and possible refinement of the new CPC in hospital psychiatry. Classical psychedelics are more likely to expand through carefully controlled trials and academic networks than through fast clinical commercialisation. # # #